On Wednesday, the FDA accepted ARS Prescribed drugs, Inc.’s SPRY neffy 1 mg (epinephrine nasal spray) for Kind I Allergic Reactions, together with anaphylaxis, in youngsters who’re aged 4 years and older and weigh 15 to < 30 kilograms.
The approval represents the primary vital innovation within the supply of epinephrine for this affected person inhabitants in additional than 35 years.
Approval of neffy 1 mg follows FDA approval for neffy 2 mg for youngsters and adults weighing 30kg and for EURneffy within the EU by the European Fee in August 2024.
The approval of neffy 1 mg relies on information from scientific trials, together with pharmacokinetic (PK) and pharmacodynamic (PD) responses in pediatric and grownup topics in step with these of epinephrine injection merchandise.
Opposed occasions in pediatric trials had been typically gentle and transient.
The gadget has a shelf-life of 24 months at room temperature and tolerance to temperature exposures as much as 122°F (50°C) primarily based on testing for as much as 3 months. If unintentionally frozen, it may be thawed with out impacting the product’s high quality and reliability.
Additionally Learn: ARS Prescribed drugs Inks Licensing Pact For Neffy Allergic Response Remedy, Analyst Sees Additional Inventory Upside Regardless of 200% Surge In 2024
Most commercially insured sufferers can pay not more than $25 for 2 single-use neffy gadgets by a co-pay financial savings program.
If the product isn’t lined by insurance coverage, the money value of $199 for 2 doses is out there by BlinkRx and coupon could be downloaded from GoodRx to be used at native retail pharmacies.
For sure uninsured or underinsured U.S. residents assembly eligibility standards and exhausted all different choices, the ARS Pharma Affected person Help Program will present neffy for free of charge.
William Blair analyst Lachlan Hanbury-Brown writes, “Whereas the approval was largely anticipated, we imagine it nonetheless represents an essential milestone for the corporate because it advances the launch of neffy 2 mg.”
The analyst famous that though Neffy 1 mg accounts for less than about 15% of the epinephrine market by quantity, the corporate’s analysis reveals that needle phobia is commonest in youngsters.
Many caregivers are additionally hesitant to make use of needle-based autoinjectors on their youngsters, which might drive greater adoption of neffy amongst pediatric sufferers.
Within the U.S., almost 40% of epinephrine prescriptions are for youngsters. Since its September launch, about two-thirds of Neffy 2 mg prescriptions have been for youngsters, indicating robust early adoption on this group.
Worth Motion: SPRY inventory is down 1.29% at $10.73 through the premarket session on the final verify Thursday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
